Renal cell carcinoma accounts for 3% of all tumors. Over the last decades, the prognosis of metastatic renal cell carcinoma (mRCC) has improved owing to the approval of several drugs such as tyrosine kinase inhibitors and immunotherapy. The median progression-free survival (PFS) does not exceed 8 months with the available drugs in pretreated patients with mRCC. We present a case of a patient with a long-term response to fourth-line treatment with cabozantinib. Our patient obtained a PFS of 33 months, which is much higher than that reported in literature.
VitaleMGBracardaSCosmaiL, et al. Management of kidney cancer patients: 2018 guidelines of the Italian Medical Oncology Association (AIOM). Tumori2019; 105(4 suppl): 3–12.
2.
NunnoVCubelliMMassariF.The role of the MET/AXL pathway as a new target for multikinase inhibitors in renal cell carcinoma. Exp Rev Precis Med Drug Dev2017; 2: 169–175.
3.
YakesFMChenJTanJ, et al. Cabozantinib (XL184), a novel MET and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth. Mol Cancer Ther2011; 10: 2298–2308.
4.
XieZLeeYHBoekeM, et al. MET inhibition in clear cell renal cell carcinoma. J Cancer2016; 7: 1205–1214.
5.
VaupelPMayerAHöckelM.Tumor hypoxia and malignant progression. Meth Enzymol2004; 381: 335–354.
6.
GossageLEisenTMaherER.VHL, the story of a tumour suppressor gene. Nat Rev Cancer2017; 15: 55–64.
7.
LiYYeXTanC, et al. Axl as a potential therapeutic target in cancer: role of Axl in tumor growth, metastasis and angiogenesis. Oncogene2009; 28: 3442–3255.
8.
ChoueiriTKEscudierBPowlesT, et al; METEOR Investigators. Cabozantinib versus everolimus in advanced renal-cell carcinoma. N Engl J Med2015; 373: 1814–1823.
9.
ChoueiriTKEscudierBPowlesT, et al. Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial. Lancet Oncol2016; 17: 917–927.
10.
ChoueiriTKHalabiSSanfordBL, et al. Cabozantinib versus sunitinib as initial targeted therapy for patients with metastatic renal cell carcinoma of poor or intermediate risk: the Alliance A031203 CABOSUN trial. N Engl J Med2015; 373: 1814–1823.
11.
ChoueiriTKHesselCHalabiS, et al. Cabozantinib versus sunitinib as initial therapy for metastatic renal cell carcinoma of intermediate or poor risk (Alliance A031203 CABOSUN randomised trial): progression-free survival by independent review and overall survival update. Eur J Cancer2018; 94: 115–125.
12.
SantoniMHengDYBracardaS, et al. Real-world data on cabozantinib in previously treated patients with metastatic renal cell carcinoma: focus on sequences and prognostic factors. Cancers. 2019; 12: 84.
13.
IacovelliRCiccareseCFacchiniG, et al. Cabozantinib after a previous immune checkpoint inhibitor in metastatic renal cell carcinoma: a retrospective multi-institutional analysis [erratum 2020; 15: 691]. Target Oncol2020; 15: 495–501.
14.
ProcopioGPrisciandaroMIacovelliR, et al. Safety and efficacy of cabozantinib in metastatic renal-cell carcinoma: real-world data from an Italian managed access program. Clin Genitourin Cancer2018; 16: e945–e951.
